Akero Therapeutics, Inc.
AKRO
Rang in aandelen
#3738
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Aandeelprijs
$54.65
Laatst gesynchroniseerd: 2025-12-09
Marktkapitalisatie
$4.50B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
1.37%
Land
US
Handel Akero Therapeutics, Inc. (AKRO)
Categorie
Healthcare
EPS voor Akero Therapeutics, Inc. (AKRO)
EPS per September 2025 TTM: $-3.74
Volgens de laatste financiële rapporten en de aandelenkoers van Akero Therapeutics, Inc. is de huidige EPS van het bedrijf (TTM) $-3.74. Eind 2023 had het bedrijf een EPS van $-2.89, een stijging ten opzichte van de EPS van 2022 die $-2.87 bedroeg.
EPS-geschiedenis van Akero Therapeutics, Inc. van 2017 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-3.74 | -0.27% |
| 2024 | $-3.75 | 29.76% |
| 2023 | $-2.89 | 0.70% |
| 2022 | $-2.87 | -0.69% |
| 2021 | $-2.89 | 14.68% |
| 2020 | $-2.52 | -13.10% |
| 2019 | $-2.90 | -24.68% |
| 2018 | $-3.85 | 2,306.25% |
| 2017 | $-0.16 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $17.32 | -563.10% |
US
|
|
| $-7.98 | 113.37% |
US
|
|
| $-5.29 | 41.44% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -841.71% |
NL
|
